The role of infliximab in the treatment of superficial granulomatous pyoderma of the head and neck

J Am Acad Dermatol. 2014 Nov;71(5):e222-5. doi: 10.1016/j.jaad.2014.07.057. Epub 2014 Oct 15.

Authors

Omer Ibrahim¹, Christopher G Bunick², Bhaskar Srivastava³, Rossitza Lazova⁴, Christine J Ko⁴, Kalman L Watsky³

Affiliations

¹ Department of Dermatology, Cleveland Clinic Foundation, Cleveland, Ohio.
² Department of Dermatology, Yale University, New Haven, Connecticut. Electronic address: christopher.bunick@yale.edu.
³ Department of Dermatology, Yale University, New Haven, Connecticut.
⁴ Department of Dermatology, Yale University, New Haven, Connecticut; Department of Pathology, Yale University, New Haven, Connecticut.

PMID: 25438004
DOI: 10.1016/j.jaad.2014.07.057

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Anti-Inflammatory Agents / therapeutic use
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Drug Therapy, Combination
Face
Granuloma / drug therapy*
Granuloma / pathology
Humans
Immunosuppressive Agents / therapeutic use
Infliximab
Male
Neck
Pyoderma / drug therapy*
Pyoderma / pathology
Tacrolimus / therapeutic use
Torso

Substances

Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Immunosuppressive Agents
Infliximab
Tacrolimus